Artificial intelligence in the pharmaceutical industry of Ukraine: prospects for future development

Alina Savchuk; Iryna Borysiuk; Tamara Mahanova; Tatiana Ihnatova

doi:10.57125/FEM.2023.06.30.02

Authors

Alina Savchuk NSC "Institute of Biology and Medicine", KNU named after Taras Shevchenko, Kyiv, Ukraine https://orcid.org/0000-0003-3188-3064
Iryna Borysiuk International Humanitarian University, Odessa, Ukraine https://orcid.org/0000-0003-2824-9118
Tamara Mahanova Zaporizhzhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine https://orcid.org/0000-0001-7008-3102
Tatiana Ihnatova Pylyp Orlyk International Classical University, Mykolaiv, Ukraine https://orcid.org/0000-0002-7229-6715

DOI:

https://doi.org/10.57125/FEM.2023.06.30.02

Keywords:

Pharmaceutical Industry; Artificial Intelligence; Ukraine; Healthcare Technology; Drug; Discovery; Medical Research

Abstract

Artificial Intelligence (AI) has emerged as a powerful tool with the potential to revolutionise industries across the globe. Among the many sectors AI is making a profound impact on, the pharmaceutical industry is as well experiencing significant transformations.

Aims: To assess the Current State of AI Adoption, to Examine the Regulatory and Ethical Landscape of AI Implementation and to Identify Opportunities and Challenges in Ukraine.

Methodology: A descriptive cross-sectional study

Results: Currently, 4.1 billion people worldwide have sustainable Internet access, and 2.8 billion people make purchases online. This data highlights the significant global growth of Internet users and the increasing popularity of online shopping. The average digital user is now aged between 25 and 44. It indicates a shift in the age group of individuals actively using digital technologies. This demographic change has implications for businesses targeting digital consumers. Ukraine's pharmaceutical industry lags behind neighboring countries like the Czech Republic, Russia, and Poland in terms of AI utilisation, with only 10 publications related to AI in pharmaceuticals. This suggests a potential gap in research funding, industry investment, or academic expertise that needs to be addressed. Several prominent pharmaceutical companies in Ukraine are actively integrating AI and technology into their operations. These companies are focusing on various aspects, including drug discovery, diagnostics, innovation hubs, and investments in genetics and genomics. This highlights the industry's increasing adoption of AI. The challenges include the need for high-quality data, the difficulty in recruiting AI experts, regulatory compliance, and the financial constraints of funding AI initiatives. These challenges are critical considerations for pharmaceutical firms looking to leverage AI in their operations.

Scientific Novelty: Artificial Intelligence (AI) has emerged as a powerful tool with the potential to revolutionise industries .

Conclusion: These results collectively provide insights into the evolving landscape of digital technology.

References

Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021;26:80. https://doi.org/10.1016/J.DRUDIS.2020.10.010.

Chavda V, Anand K, Apostolopoulos V. Bioinformatics Tools for Pharmaceutical Drug Product Development. Bioinformatics Tools for Pharmaceutical Drug Product Development 2023:1–421. https://doi.org/10.1002/9781119865728.

Filippova L V. Features of the development of higher pharmaceutical education in Ukraine. Pedagogical Sciences Reality and Perspectives 2021;2:97–100. https://doi.org/10.31392/NPU-NC.SERIES5.2021.84.2.20.

Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers 2021;25:1315–60. https://doi.org/10.1007/S11030-021-10217-3.

Kondratov IS, Moroz YS, Grygorenko OO, Tolmachev AA. The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd. ACS Med Chem Lett 2022;13:992. https://doi.org/10.1021/ACSMEDCHEMLETT.2C00211.

Shevchenko AI, Glushkov Ave A, Bilokobylsky O V, Vakulenko MO, Dovbysh AS, Kazimir V V, et al. Regarding the draft strategy development of Artificial Intelligence in Ukraine. Jai.inUa n.d.;37:3057. https://doi.org/10.15407/jai2022.01.008.

Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sensors International 2021;2:100117. https://doi.org/10.1016/J.SINTL.2021.100117.

Vokinger KN, Gasser U. Regulating AI in medicine in the United States and Europe. Nat Mach Intell 2021;3:738. https://doi.org/10.1038/S42256-021-00386-Z.

Kondratov IS, Moroz YS, Grygorenko OO, Tolmachev AA. The Ukrainian Factor in Early-Stage Drug Discovery in the Context of Russian Invasion: The Case of Enamine Ltd. ACS Med Chem Lett 2022;13:992. https://doi.org/10.1021/ACSMEDCHEMLETT.2C00211.

Iryna T, Iryna B, Volodymyr M. Digitalization of Pharmaceutical Business in Ukraine. Res J Pharm Technol 2022;15:1555–9. https://doi.org/10.52711/0974-360X.2022.00259.

Haque U, Naeem A, Wang S, Espinoza J, Holovanova I, Gutor T, et al. The human toll and humanitarian crisis of the Russia-Ukraine war: the first 162 days. BMJ Glob Health 2022;7. https://doi.org/10.1136/BMJGH-2022-009550.

Eiben H, Hala L, Slipchuk V. The Current State of the Pharmaceutical Market of Ukraine, Quality Assurance and Falfication of Medicines. Pharmacia 2021;68:411–9. https://doi.org/10.3897/PHARMACIA.68.E64723.

Chumachenko D, Chumachenko T. Ukraine war: The humanitarian crisis in Kharkiv. The BMJ 2022. https://doi.org/10.1136/BMJ.O796.

Yang Z, Sun F, Chen DH, Wang ZQ, Wang CK, Li ZL, et al. Current spin polarization of a platform molecule with compression effect. Chinese Physics B 2022;31. https://doi.org/10.1088/1674-1056/AC4F53.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6. https://doi.org/10.1038/S41421-020-0156-0.

Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today 2021;26:80–93. https://doi.org/10.1016/J.DRUDIS.2020.10.010.

Xu Y, Liu X, Cao X, Huang C, Liu E, Qian S, et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation 2021;2. https://doi.org/10.1016/J.XINN.2021.100179.

Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 2020;580:663–8. https://doi.org/10.1038/S41586-020-2117-Z.

Kulkov I, Hellström M, Wikström K. Identifying the role of business accelerators in the developing business ecosystem: the life science sector. European Journal of Innovation Management 2020;24:1459–79. https://doi.org/10.1108/EJIM-04-2020-0139.

Kulkov I. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technol Soc 2021;66:101629. https://doi.org/10.1016/J.TECHSOC.2021.101629

Artificial intelligence in the pharmaceutical industry of Ukraine: prospects for future development

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

How to Cite

Issue

Section

License

issn

Make a Submission

quicklinks

Other journals